EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical outcomes and genomic profiles of MAP2K1-mutated primary cutaneous melanocytic tumours

Chiel F Ebbelaar, Anne M L Jansen, Leonie C M Speet, Frans Schutgens, Sietske Zoetemeyer, Anne-Marie Cleton-Jansen, Marijke R van Dijk, Gerben E Breimer, Lourens T Bloem, Wendy W J de Leng, Remco van Doorn, Karijn P M Suijkerbuijk und 3 weitere

eBioMedicine · 2025

DOI: 10.1016/j.ebiom.2025.105643 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eBioMedicine, 2025. Verfasst von Chiel F Ebbelaar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Leiden University Medical Centre, Leiden, the Netherlands; Department of Pathology, University Medical Centre Utrecht, Utr…. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Mutation, Genomics. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hanarth Fund Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Primary cutaneous melanocytic tumours harbouring MAP2K1 mutations without second-hit genomic alterations represent a subclass of neoplasms with poorly understood biological behaviour. This study aimed to investigate the clinical outcomes and genomic characteristics of these tumours. METHODS: This cohort study included primary cutaneous melanocytic tumours with MAP2K1 mutations from patients at two academic centres (Leiden University Medical Centre and University Medical Centre Utrecht). These mutations were categorised into three functional classes: Class I (RAF-dependent), Class II (RAF-regulated), and Class III (RAF-independent). Tumours underwent histopathological evaluation, next-generation sequencing (NGS), and copy number variation (CNV) analysis and were categorised as non-melanoma or melanoma. Clinical outcomes were assessed for each mutation class during follow-up visits and through the Dutch Pathology Database (PALGA) using the composite outcome of metastatic melanoma (recurrence, metastasis, or melanoma-related death). FINDINGS: A total of 102 patients were included, with tumours classified as melanoma in 52 (51%) and non-melanoma in 50 (49%). The tumours displayed spitzoid histomorphology in over two-thirds of cases and harboured 31 distinct MAP2K1 mutations: 20 Class I (19.6%), 56 Class II (54.9%), and 26 Class III (25.5%). Class I mutations exclusively co-occurred with BRAF or NRAS mutations, while Class II and III mutations often acted as sole tumour drivers. Of the tumours with Class I mutations, 95% were classified as melanoma, which was less frequently the case for Class II (risk ratio [RR] 0.43 [95% CI: 0.31-0.60], p < 0.001) and Class III mutations (RR 0.40 [95% CI: 0.25-0.67], p < 0.001). MAP2K1 mutation Class and TERT-p mutation status were independent predictors for the composite outcome. Compared to Class I mutations, Class II mutations were negatively associated with the composite outcome (odds ratio [OR] 0.16 [95% CI: 0.03-0.75], p = 0.03), whereas Class III mutations were not associated (OR 0.31 [95% CI: 0.05-1.54], p = 0.16). TERT-p mutations were positively associated with the composite outcome (OR 23.1, 95% CI: 3.99-439.8, p < 0.005). INTERPRETATION: Class I MAP2K1 mutations typically occur alongside other MAPK pathway mutations and may contribute to aggressive melanoma behaviour. In contrast, Class II and III MAP2K1 mutations can independently drive melanocytic tumourigenesis with a potential for metastasis, aligning with conventional melanomagenesis pathways, despite their frequent spitzoid histomorphology. FUNDING: This research was supported by the Hanarth Fund.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsMutationGenomicsMAP Kinase Kinase 1HumansFemaleMaleMiddle AgedAgedAdultDNA Copy Number VariationsHigh-Throughput Nucleotide SequencingPrognosisAged, 80 and overCutaneous Malignant Melanoma

Stichwörter der Autor:innen

MAP2K1 mutationsMelanomaMetastasisMolecular oncologyPrognosis

Substanzen

MAP2K1 protein, humanMAP Kinase Kinase 1

Autor:innen und Institutionen

  • Department of Dermatology, Leiden University Medical Centre, Leiden, the Netherlands; Department of Pathology, University Medical Centre Utrecht, Utrecht, the Netherlands. Electronic address: c.f.ebbelaar@lumc.nl.
  • Department of Dermatology, Leiden University Medical Centre, Leiden, the Netherlands.
  • Department of Pathology, Leiden University Medical Centre, Leiden, the Netherlands; Department of Pathology, Symbiant, Hoorn, the Netherlands.
  • Department of Pathology, University Medical Centre Utrecht, Utrecht, the Netherlands.
  • Department of Pathology, Reinier de Graaf Gasthuis, Delft, the Netherlands.
  • Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands.

Förderung

  • Hanarth Fund Foundation

Zitieren

APA

Ebbelaar, C. F., Jansen, A. M. L., Speet, L. C. M., Schutgens, F., Zoetemeyer, S., Cleton-Jansen, A. M., van Dijk, M. R., Breimer, G. E., Bloem, L. T., de Leng, W. W. J., van Doorn, R., Suijkerbuijk, K. P. M., Schrader, A. M. R., Blokx, W. A. M., & MOLecular Evaluation of Melanocytic Ambiguous Tumours (MOLEMAT) Investigators (2025). Clinical outcomes and genomic profiles of MAP2K1-mutated primary cutaneous melanocytic tumours. eBioMedicine. https://doi.org/10.1016/j.ebiom.2025.105643

Vancouver

Ebbelaar CF, Jansen AML, Speet LCM, Schutgens F, Zoetemeyer S, Cleton-Jansen AM, et al. Clinical outcomes and genomic profiles of MAP2K1-mutated primary cutaneous melanocytic tumours. eBioMedicine. 2025. doi:10.1016/j.ebiom.2025.105643

BibTeX
@article{Ebbelaar2025,
  author = {Ebbelaar, Chiel F and Jansen, Anne M L and Speet, Leonie C M and Schutgens, Frans and Zoetemeyer, Sietske and Cleton-Jansen, Anne-Marie and van Dijk, Marijke R and Breimer, Gerben E and Bloem, Lourens T and de Leng, Wendy W J and van Doorn, Remco and Suijkerbuijk, Karijn P M and Schrader, Anne M R and Blokx, Willeke A M and MOLecular Evaluation of Melanocytic Ambiguous Tumours (MOLEMAT) Investigators, MOLecular Evaluation of Melanocytic Ambiguous Tumours (MOLEMAT) Investigators},
  title = {Clinical outcomes and genomic profiles of MAP2K1-mutated primary cutaneous melanocytic tumours},
  journal = {eBioMedicine},
  year = {2025},
  doi = {10.1016/j.ebiom.2025.105643}
}
Kostenlos starten →